CR
CRISPR Therapeutics
CRSP · NASDAQ
$54.78 +0.61% (+$0.33)
1M +4.26%
Market Cap $5.28B
P/E Ratio -
Div. Yield -
ROE 24.39%
Bulios Fair Price
$38.68
29.4% downside
Current Price
$54.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRSP is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
33 /100
Expensive P/S 394.52x
P/B 3.03x
P/E N/A
Growth
84 /100
Growing Rev. growth 100.42%
Book val. growth 0.82%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 1,534.39%
FCF margin 3,589.65%
Net margin 3,368.72%
Quality
0 /100
Poor ROIC 21.11%
Asset turnover 0.01x
ROE 24.39%
Debt
92 /100
Low Debt/Equity 0.45x
Current ratio 17.85x
Int. coverage N/A
Stability
4 /100
Unstable Beta 1.74x
Profitable years 0
Rev. volatility 48,989.70%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRSP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Samarth Kulkarni
Employees
393
Headquarters
Zug
Upcoming events
09 NOV
Earnings
Upcoming earnings report